COLLEGIUM PHARMACEUTICAL INC (COLL)
Health Care · Specialty Pharmaceuticals · NASDAQ
A diversified biopharmaceutical firm managing a portfolio of ADHD treatments and chronic pain management therapies.
What COLLEGIUM PHARMACEUTICAL INC does
Collegium Pharmaceutical is a biopharmaceutical company focused on the acquisition, development, and commercialization of products for the treatment of ADHD and moderate to severe pain. Its portfolio includes CNS stimulants like Jornay PM and Azstarys for ADHD, as well as a range of opioid-based pain therapies including Belbuca, Xtampza ER, and Nucynta products. The company primarily operates within the United States.
Themes: ADHD treatments, pain management, central nervous system (CNS) medicine, opioid therapies, specialty pharmaceuticals
Fundamentals
- Price$22.11 as of 2026-10-08 close
- Market cap$720M as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return-33.3% 2025-10-08 close $33.13 → 2026-10-08 close $22.11
- P/E19.84 as of 2026-10-08
- Net margin+8.1% FY2025, SEC XBRL
- Gross margin+59.3% FY2025, SEC XBRL
- ROE+20.8% FY2025, SEC XBRL
- Debt / equity3.89 as of 2026-09-03
- Revenue growth (YoY)+14.3% as of 2026-09-03
- Revenue CAGR (3y)+18.9% SEC XBRL
- Beta0.52 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How COLL compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How COLLEGIUM PHARMACEUTICAL INC looks technically
COLLEGIUM PHARMACEUTICAL INC (COLL) is trading 37.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 122 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 7 trading days ago. It is 3.2% above its 52-week low (its lowest price of the past year). Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 37.5% below its 200-day average, the long-term trend line — a long-term downtrend | -37.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $25.65 | $25.65 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $35.35 | $35.35 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed five-part downward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes below 21.43. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave downward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 122 trading days ago — a "death cross", a bearish long-term signal | 122 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with sellers in control | 39.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30) | 34.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($21.43 to $23.69) — its "stochastic" reading is 30 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 30.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $50.79 | $50.79 |
|---|---|---|
| From the 52-week high | it is 56.5% below its 52-week high (its highest price of the past year) | -56.5% |
| Above the 52-week low | it is 3.2% above its 52-week low (its lowest price of the past year) | +3.2% |
| Below the 52-week high | it is 56.5% below its highest point of the past year | 56.5% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day low about 7 trading days ago | 7 sessions |
| All-time high | its highest closing price on record is $50.79 (set on 2025-12-29) | $50.79 |
| Given back of the 52-week move | over the past year its closes ranged ($21.82 to $49.84), and it has recovered essentially none of its fall from last year’s high — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $39.14 to $40.03. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.0% |
| From the all-time high | it is 56.5% below its all-time high | -56.5% |
| Nearest price level | it is trading 2.6% above a support level at $21.54 — a price it turned at twice since 2026-09-15, most recently on 2026-10-01. Since 2024-10-08 it has 1 such level below the current price and 15 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.6% |
| All-time low | its lowest closing price on record is $7.37 (set on 2017-05-09) | $7.37 |
| Above the all-time low | it is 200.0% above its all-time low | +200.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8617 between its high and its low — about 3.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8617 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $21.55 and $23.10 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $21.55 – $22.33 – $23.10 |
| Typical daily range (% of price) | its price moves about 3.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.9% |
| Stretch from the 200-day average | it is trading 15.4 daily ranges below its 200-day average price (37.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 15.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.58× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Open gap | it gapped 11.4% below the previous close 44 sessions ago and has not traded back through the level it left behind at 35.74 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -11.4% |
| Gap filled | a 7.9% gap up opened on 2026-08-13 has been "filled" 28 sessions ago — price traded back through the level the gap left behind, and it took 11 sessions to close | 28 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +1.1% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.4 percentage points (the stock lost 5.4% while the market gained 1.0%) | -6.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 42.1 percentage points (the stock lost 38.3% while the market gained 3.8%) | -42.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 49.6 percentage points (the stock lost 32.2% while the market gained 17.5%) | -49.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 48.2 percentage points (the stock lost 33.3% while the market gained 15.0%) | -48.2% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 22% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 13.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -21.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 32% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $32.71 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -32.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 10% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $24.66 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -10.3% |
Price levels it has turned at before
COLL last closed at $22.11 on 2026-10-08. Since 2024-10-08 it has turned at 1 price below its last close and 15 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $21.54 | Support | 2.6% below the last close | turned there twice · 2026-09-15 to 2026-10-01 |
| $28.23 | Resistance | 27.7% above the last close | turned there three times · 2025-01-03 to 2025-05-23 |
| $29.19 | Resistance | 32.0% above the last close | turned there four times · 2024-11-18 to 2025-08-01 |
| $29.95 | Resistance | 35.4% above the last close | turned there three times · 2025-03-11 to 2026-08-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $21.43.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 1 trading day, since 2026-10-08.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · lagging the market · Stretched far below its 200-day average (6+ daily ranges) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$49.00 range $43.00 – $60.00; median $48.50
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for COLL
- Consensus EPS estimate$1.80 next reporting period, as of 2026-10-08
- Estimate change, 30 days-$0.06307 (-3.4%) from $1.86, on 2026-09-03, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant exposure to opioid-related litigation, investigations, and evolving regulatory restrictions.","Heavy reliance on a limited portfolio of products, increasing risks associated with market acceptance, competition, and generic erosion.","Challenges in managing high levels of indebtedness and integrating newly acquired assets like Azstarys and Ironshore products."]
What changed in the latest 10-Q
AI-assisted comparison of COLL's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states the company began recognizing product revenue related to Azstarys in May 2026 following the Azstarys Acquisition.
- Newer filing includes an Azstarys product description paragraph: 'Azstarys is a CNS stimulant prescription medicine that contains serdexmethylphenidate and dexmethylphenidate approved by the FDA in March 2021 for the treatment of ADHD in people six years of age and older.'
- Newer filing adds 'Changes in our critical accounting policies with respect to our Annual Report include business combination accounting and valuation of acquired assets, including goodwill and intangible assets, as described below.'
- Newer filing adds a section titled 'Business Combination Accounting and Valuation of Acquired Net Assets' describing the Azstarys Acquisition on May 12, 2026, including purchase price allocation, goodwill measurement, and valuation methods.
- Newer filing lists Azstarys among commercialized products in the United States.
- Removed:
- Older filing's Overview begins with 'Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.' This sentence is removed in the newer filing.
- Older filing includes a paragraph on the Azstarys Purchase Agreement (entered March 19, 2026) describing the pending acquisition, purchase price of $650 million in cash, milestone payments of up to $135 million, expected funding, and expected closing in the second quarter of 2026. This paragraph is removed in the newer filing.
- Older filing includes a 'Results of Operations' section with three-month comparison tables and discussion; this appears absent from the newer filing excerpt provided.
- Reworded:
- Newer filing replaces 'Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions' with 'We are a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions.'
- Older filing lists commercialized products as 'Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR, Nucynta ER Authorized Generic ("AG"), and Nucynta IR AG (collectively the "Nucynta Products"), and Symproic'; newer filing inserts Azstarys into this list.
- Older filing describes Azstarys as a pending acquisition expected to close in Q2 2026; newer filing describes Azstarys as a completed acquisition with product revenue recognition beginning May 2026.
- Notes:
- The newer filing excerpt appears truncated after the Business Combination Accounting section, so changes after that point cannot be assessed.
- The older filing includes a Results of Operations section that is not present in the newer filing excerpt; it is unclear whether that section was removed or simply not included in the provided excerpt.
Risk Factors
- Added:
- Newer filing (filed 2026-08-06) added a bullet: 'Our ability to realize the benefits of the acquisition of Azstarys is substantially dependent on the timely and effective integration of Azstarys;'
- Newer filing (filed 2026-08-06) changed the distribution bullet to: 'We depend on wholesale pharmaceutical distributors and other distribution partners for distribution of our products; if we lose any significant distributor or distribution partner, or its distribution network is disrupted, our financial condition and results of operations may be adversely affected;'
- Removed:
- Older filing (filed 2026-05-07) contained a bullet: 'The announcement and pendency of our acquisition of AZSTARYS ® may have an adverse effect on our business, financial condition, operating results and cash flows;' which was removed in the newer filing.
- Older filing (filed 2026-05-07) contained a bullet: 'We depend on wholesale pharmaceutical distributors for retail distribution of our products; if we lose any of our significant wholesale pharmaceutical distributors or their distribution network is disrupted, our financial condition and results of operations may be adversely affected;' which was removed in the newer filing.
- Reworded:
- Newer filing (filed 2026-08-06) changed the wording of the distribution bullet from 'We depend on wholesale pharmaceutical distributors for retail distribution of our products; if we lose any of our significant wholesale pharmaceutical distributors or their distribution network is disrupted...' to 'We depend on wholesale pharmaceutical distributors and other distribution partners for distribution of our products; if we lose any significant distributor or distribution partner, or its distribution network is disrupted...'
- Newer filing (filed 2026-08-06) changed 'Azstarys' formatting from 'AZSTARYS ®' (older filing, filed 2026-05-07) to 'Azstarys' without the registered trademark symbol.
- Page number shown in Table of Contents changed from 45 (older filing, filed 2026-05-07) to 53 (newer filing, filed 2026-08-06).
- Notes:
- The newer filing excerpt ends mid-sentence ('including our ability to:'), so full comparison of the remaining risk factor text was not possible.
- The older filing excerpt ends mid-sentence ('...any other products that we may in-license'), so full comparison of the remaining risk factor text was not possible.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 4 sells ($628580) — 3 selling insiders
Most recent open-market transaction: 2026-05-18. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about COLL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding COLL as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,581,305
- Reported value $310,643,241
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about COLL's institutional holders → See what each manager we track holds →
Short interest (FINRA)
COLL had 5,675,115 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
COLL had 17.4% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.03 days to cover at the same settlement.
- Reported short interest (shares) 5,675,115
- Short interest (% of shares outstanding) 17.4%
- Prior settlement (shares) 6,063,781
- Reported change -6.41%
- Days to cover (reported) 6.03
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Purdue Pharma
- Teva Pharmaceutical (TEVA)
- Hikma Pharmaceuticals
- Supernus Pharmaceuticals (SUPN)
- Assertio Holdings (ASRT)
- Endo International
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare COLL vs…
Frequently asked questions
What does COLLEGIUM PHARMACEUTICAL INC (COLL) do?
Collegium Pharmaceutical is a biopharmaceutical company focused on the acquisition, development, and commercialization of products for the treatment of ADHD and moderate to severe pain. Its portfolio includes CNS stimulants like Jornay PM and Azstarys for ADHD, as well as a range of opioid-based pain therapies including Belbuca, Xtampza ER, and Nucynta products. The company primarily operates within the United States.
What sector is COLLEGIUM PHARMACEUTICAL INC (COLL) in?
COLLEGIUM PHARMACEUTICAL INC (COLL) is classified in the Health Care sector. Its industry is Specialty Pharmaceuticals. It trades on NASDAQ.
Who are COLLEGIUM PHARMACEUTICAL INC's (COLL) competitors?
Notable peers of COLLEGIUM PHARMACEUTICAL INC (COLL) include Purdue Pharma, Teva Pharmaceutical, Hikma Pharmaceuticals, Supernus Pharmaceuticals and Assertio Holdings. This peer set is informational only — not financial advice.
Is COLLEGIUM PHARMACEUTICAL INC (COLL) overbought or oversold right now?
COLLEGIUM PHARMACEUTICAL INC (COLL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 34, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on COLL come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.